A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).
Authors:
- A. T. PhanAPA. T. Phan
- J. C. YaoJYJ. C. Yao
- D. R. FogelmanDFD. R. Fogelman
- K. R. HessKHK. R. Hess
- C. S. NgCNC. S. Ng
- S. A. BullockSBS. A. Bullock
- P. MalinowskiPMP. Malinowski
- E. ReganERE. Regan
- M. KulkeMKM. Kulke
- 20 May 2010
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 4001